A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Mirati Therapeutics Inc.
Study ID
NCT07415031
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Adagrasib — DRUG
    Specified dose on specified days
  • Pembrolizumab — DRUG
    Specified dose on specified days
  • Cetuximab — DRUG
    Specified dose on specified days
  • Pemetrexed — DRUG
    Specified dose on specified days
  • Docetaxel — DRUG
    Specified dose on specified days
  • Irinotecan — DRUG
    Specified dose on specified days
  • Leucovorin — DRUG
    Specified dose on specified days
  • Oxaliplatin — DRUG
    Specified dose on specified days
  • Fluorouracil — DRUG
    Specified dose on specified days

Study Details

This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.

Key Dates

Start date
May 6, 2026
Status verified
May 2026
Primary completion
Feb 16, 2028
Completion
Feb 16, 2028

Study Design

Enrollment
170 participants (estimated)
Allocation
NA
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A1
  • Experimental: Arm A2
  • Experimental: Arm B1
  • Experimental: Arm B2
  • Experimental: Arm B3
  • Experimental: Arm B4
  • Experimental: Arm C1
  • Experimental: Arm C2
  • Experimental: Arm C3
  • Experimental: Arm C4

Primary Outcome Measure

Number of Participants With Adverse Events (AEs) [ Time Frame: Up to 90 days from last dose or study discontinuation ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (17)

FacilityCityStateZIPSite coordinators
Local Institution - 0005PhoenixArizona85054-
Local Institution - 0016BellflowerCalifornia90706
Site 0016
Local Institution - 0082Long BeachCalifornia90806
Site 0082
Local Institution - 0003NewarkDelaware19713-
Local Institution - 0001St. PetersburgFlorida33701
Site 0001
Local Institution - 0064ChicagoIllinois60637
Site 0064
Local Institution - 0112WichitaKansas67208
Site 0112
Local Institution - 0080BostonMassachusetts02215
Site 0080
Local Institution - 0092BostonMassachusetts00215
Site 0092
Mayo Clinic in Rochester, MinnesotaRochesterMinnesota55905
Konstantinos Leventakos, Site 0017
507-284-2511
Local Institution - 0073Saint PaulMinnesota55101
Site 0073
Local Institution - 0036OmahaNebraska68114
Site 0036
Local Institution - 0116New YorkNew York10065 6800
Site 0116
Local Institution - 0004EugeneOregon97401
Site 0004
Local Institution - 0023GermantownTennessee38138
Site 0023
Local Institution - 0002GrapevineTexas76051
Site 0002
Local Institution - 0013BellinghamWashington98225
Site 0013

Find similar trials in Phoenix, AZ

By research site
Local Institution - 0005· Phoenix, AZLocal Institution - 0016· Bellflower, CALocal Institution - 0082· Long Beach, CALocal Institution - 0003· Newark, DELocal Institution - 0001· St. Petersburg, FLLocal Institution - 0064· Chicago, IL

Related Studies